Clinical Research

Opthea Limited

Address
650 Chapel Street

Sponsor Overview

assignment
2
sponsored trials
science
3
molecules
location_city
96
research centres
public
17
countries
person_search
98
investigators

Specializations

Retinal Disease and Neovascular Age-related Macular Degeneration

Opthea Limited’s clinical research is centered on neovascular age-related macular degeneration (wet AMD), with studies focused on vision-threatening retinal disease and the treatment of abnormal blood vessel growth in the macula.

  • Wet AMD
  • Neovascular macular disease

The sponsor’s trials examine treatment strategies for patients with active retinal vascular disease in multiple international sites.

Anti-VEGF Combination Therapy

The research portfolio includes combination approaches pairing OPT-302 with established anti-VEGF therapies, reflecting a therapeutic interest in enhancing management of choroidal neovascularization in wet AMD.

  • OPT-302
  • Aflibercept
  • Ranibizumab

These studies are directed toward improving outcomes in patients receiving intravitreal treatment for macular degeneration.

Ophthalmology and Visual Function

Opthea’s clinical activity is firmly within ophthalmology, with a therapeutic emphasis on preserving vision in people affected by degenerative retinal conditions.

  • Retinal specialist care
  • Macular edema
  • Central vision loss

The sponsor’s research sites span multiple countries, supporting study access for patients with advanced ocular disease.

Sponsored Trials

Trial Name Country Status
Evaluation of Intravitreal OPT-302 and Aflibercept Versus Aflibercept Monotherapy in Neovascular Age-related Macular Degeneration PatientsAustria AustriaBulgaria BulgariaCroatia CroatiaCzechia CzechiaEstonia EstoniaFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyLatvia LatviaLithuania LithuaniaPoland PolandSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting
Evaluation of Intravitreal OPT-302 and Ranibizumab Versus Ranibizumab Monotherapy in Neovascular Age-related Macular DegenerationCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyLatvia LatviaPoland PolandSpain SpainNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 3 total (33% not shared with other sponsors)

This sponsor works with 3 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
2%
Return partnership rate
2 of 96 sites collaborated multiple times

This sponsor has worked with 96 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Eye Diseases2 trials
    138 other sponsors

Partnered Research Centres

96 centres
location_city
assignment352
Aarhus University Hospital
Address
Palle Juul-Jensens Boulevard 99, 8200 Aarhus
Learn morearrow_forward
location_city
assignment86
Area De Salud De Burgos Y Soria
Address
Avenida De Las Islas Baleares 3, 09006 Burgos
Learn morearrow_forward
location_city
assignment153
ASST Fatebenefratelli Sacco
Address
Via Giovanni Battista Grassi 74, 20157 Milan
Learn morearrow_forward
location_city
assignment46
Axon Clinical s.r.o.
Address
Ostrovskeho 253/3, Smichov, 150 00 Prague
Learn morearrow_forward
location_city
assignment226
Azienda Ospedaliera Universitaria Senese
Address
Strada Delle Scotte 14, 53100 Siena
Learn morearrow_forward
location_city
assignment624
Azienda Ospedaliero Universitaria Careggi
Address
Largo Giovanni Alessandro Brambilla 3, 50134 Florence
Learn morearrow_forward
Page 1 of 16

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Opthea Limited.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.